Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 53Not yet recruiting 17Active not recruiting 16Completed 4Terminated 3Withdrawn 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1

Interventions

Radiation 4fludarabine 2daratumumab 2Temozolomide 2Specimen Handling 2Radiotherapy 2Irinotecan 2Gemcitabine 2Cytarabine 2Biopsy 2ALT-803 2vocimagene amiretrorepvec 1revumenib 1pembrolizumab 1pelcitoclax 1olutasidenib 1merphos 1irinotecan sucrosofate 1dexamethasone acetate 1dexamethasone 21-phosphate 1dehydroftorafur 1decitabine and cedazuridine drug combination 1carfilzomib 1balstilimab 1auricularum 1X-Rays 1Vorinostat 1Transurethral Resection of Prostate 1Taxes 1Surveys and Questionnaires 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × fludarabine × 30 days × Clear all
NCT06698744 2026-05-13

UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma

Case Comprehensive Cancer Center

Phase 1 Withdrawn
Plasma cell

Multiple Myeloma

NCT07428486 2026-05-07

A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡